GSK (LSE/NYSE: GSK) has entered into agreements with Hengrui Pharma to develop up to 12 innovative medicines across various therapeutic areas, including Respiratory, Immunology & Inflammation and Oncology. The collaborations aim to expand GSK’s pipeline beyond 2031.
HRS-9821, a PDE3/4 inhibitor, is being developed for the treatment of chronic obstructive pulmonary disease (COPD). This potential best-in-class medicine has demonstrated potent inhibition in early clinical and preclinical studies, leading to increased bronchodilation and anti-inflammatory effects. The agreement includes an exclusive worldwide license for HRS-9821, with GSK paying $500 million upfront.
In addition, the companies will collaborate on 11 other programmes, each with its own financial structure. Hengrui Pharma will lead the development of these programmes up to phase I trials, while GSK will have the option to further develop and commercialize each programme worldwide.
The collaboration is expected to bring significant growth opportunities for GSK beyond 2031. The potential total value of future milestone payments to Hengrui Pharma is approximately $12 billion if all programmes are optioned and milestones are achieved.
This strategic partnership marks a milestone in Hengrui Pharma’s globalization journey, with the company aiming to deliver higher-quality therapies to patients worldwide. GSK brings its expertise in therapy areas, disease biology, clinical development capabilities, and global commercial scale to accelerate the development of innovative medicines.
Source: https://www.gsk.com/en-gb/media/press-releases/gsk-and-hengrui-pharma-enter-agreements